Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan 2;1(1):CD010206.
doi: 10.1002/14651858.CD010206.pub2.

Palliative pharmacological sedation for terminally ill adults

Elaine M Beller  1 , Mieke L van Driel, Leanne McGregor, Shani Truong, Geoffrey Mitchell
Affiliations

Palliative pharmacological sedation for terminally ill adults

Elaine M Beller et al. Cochrane Database Syst Rev. .

Abstract

Background: Terminally ill people experience a variety of symptoms in the last hours and days of life, including delirium, agitation, anxiety, terminal restlessness, dyspnoea, pain, vomiting, and psychological and physical distress. In the terminal phase of life, these symptoms may become refractory, and unable to be controlled by supportive and palliative therapies specifically targeted to these symptoms. Palliative sedation therapy is one potential solution to providing relief from these refractory symptoms. Sedation in terminally ill people is intended to provide relief from refractory symptoms that are not controlled by other methods. Sedative drugs such as benzodiazepines are titrated to achieve the desired level of sedation; the level of sedation can be easily maintained and the effect is reversible.

Objectives: To assess the evidence for the benefit of palliative pharmacological sedation on quality of life, survival, and specific refractory symptoms in terminally ill adults during their last few days of life.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 11), MEDLINE (1946 to November 2014), and EMBASE (1974 to December 2014), using search terms representing the sedative drug names and classes, disease stage, and study designs.

Selection criteria: We included randomised controlled trials (RCTs), quasi-RCTs, non-RCTs, and observational studies (e.g. before-and-after, interrupted-time-series) with quantitative outcomes. We excluded studies with only qualitative outcomes or that had no comparison (i.e. no control group or no within-group comparison) (e.g. single arm case series).

Data collection and analysis: Two review authors independently screened titles and abstracts of citations, and full text of potentially eligible studies. Two review authors independently carried out data extraction using standard data extraction forms. A third review author acted as arbiter for both stages. We carried out no meta-analyses due to insufficient data for pooling on any outcome; therefore, we reported outcomes narratively.

Main results: The searches resulted in 14 included studies, involving 4167 adults, of whom 1137 received palliative sedation. More than 95% of people had cancer. No studies were randomised or quasi-randomised. All were consecutive case series, with only three having prospective data collection. Risk of bias was high, due to lack of randomisation. No studies measured quality of life or participant well-being, which was the primary outcome of the review. Five studies measured symptom control, using four different methods, so pooling was not possible. The results demonstrated that despite sedation, delirium and dyspnoea were still troublesome symptoms in these people in the last few days of life. Control of other symptoms appeared to be similar in sedated and non-sedated people. Only one study measured unintended adverse effects of sedative drugs and found no major events; however, four of 70 participants appeared to have drug-induced delirium. The study noticed no respiratory suppression. Thirteen of the 14 studies measured survival time from admission or referral to death, and all demonstrated no statistically significant difference between sedated and non-sedated groups.

Authors' conclusions: There was insufficient evidence about the efficacy of palliative sedation in terms of a person's quality of life or symptom control. There was evidence that palliative sedation did not hasten death, which has been a concern of physicians and families in prescribing this treatment. However, this evidence comes from low quality studies, so should be interpreted with caution. Further studies that specifically measure the efficacy and quality of life in sedated people, compared with non-sedated people, and quantify adverse effects are required.

PubMed Disclaimer

Conflict of interest statement

EB has no known conflicts of interest to declare that are relevant to this review.

MvD has no known conflicts of interest to declare that are relevant to this review.

LM has no known conflicts of interest to declare that are relevant to this review.

ST has no known conflicts of interest to declare that are relevant to this review.

GM has no known conflicts of interest to declare that are relevant to this review.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD010206

References

References to studies included in this review

Alonso‐Babarro 2010 {published data only}
    1. Alonso‐Babarro A, Varela‐Cerdeira M, Rodriguez‐Barrientos R, Bruera E. At‐home palliative sedation for end‐of‐life cancer patients. Palliative Medicine 2010;24(5):486‐92. - PubMed
Bulli 2007 {published data only}
    1. Bulli F, Miccinesi G, Biancalani E, Fallai M, Mannocci M, Paci E, et al. Continuous deep sedation in home palliative care units: case studies in the Florence area in 2000 and 2003‐2004. Minerva Anestesiologica 2007;73:291‐8. - PubMed
Caraceni 2012 {published data only}
    1. Caraceni A, Zecca E, Martini C, Gorni G, Campa T, Brunelli C, et al. Palliative sedation at the end of life at a tertiary cancer center. Supportive Care in Cancer 2012;20:1299‐307. - PubMed
Chiu 2001 {published data only}
    1. Chiu TY, Hu WY, Lue BH, Cheng SY, Chen CY. Sedation for refractory symptoms of terminal cancer patients in Taiwan. Journal of Pain and Symptom Management 2001;21(6):467‐72. - PubMed
Fainsinger 1998 {published data only}
    1. Fainsinger RL, Landman W, Hoskings M, Bruera E. Sedation for uncontrolled symptoms in a South African hospice. Journal of Pain and Symptom Management 1998;16(3):145‐52. - PubMed
Kohara 2005 {published data only}
    1. Kohara H, Ueoka H, Takeyama H, Murakami T, Morita T. Sedation for terminally ill patients with cancer with uncontrollable physical distress. Journal of Palliative Medicine 2005;8(1):20‐5. - PubMed
Maltoni 2009 {published data only}
    1. Maltoni M, Pittureri C, Scarpi E, Piccinini L, Martini F, Turci P, et al. Palliative sedation therapy does not hasten death: results from a prospective multicenter study. Annals of Oncology 2009;20:1163‐9. - PubMed
Maltoni 2012b {published data only}
    1. Maltoni M, Miccinesi G, Morino P, Scarpi E, Bulli F, Martini F, et al. Prospective observational Italian study on palliative sedation in two hospice settings: differences in case mixes and clinical care. Supportive Care in Cancer 2012;20:2829‐36. - PubMed
Muller‐Busch 2003 {published data only}
    1. Muller‐Busch HC, Andres I, Jehser T. Sedation in palliative care ‐ a critical analysis of 7 years experience. BMC Palliative Care 2003;2:2. - PMC - PubMed
Radha Krishna 2012 {published data only}
    1. Radha Krishna LK, Poulose VJ, Goh C. The use of midazolam and haloperidol in cancer patients at the end of life. Singapore Medical Journal 2012;53(1):62‐6. - PubMed
Rietjens 2008 {published data only}
    1. Rietjens JAC, Zuylen L, Veluw H, Wijk L, Heide A, Rijt CCD. Palliative sedation in a specialized unit for acute palliative care in a cancer hospital: comparing patients dying with and without palliative sedation. Journal of Pain and Symptom Management 2008;36(3):228‐34. - PubMed
Stone 1997 {published data only}
    1. Stone P, Phillips C, Spruyt O, Waight C. A comparison of the use of sedatives in a hospital support team and in a hospice. Palliative Medicine 1997;11:140‐4. - PubMed
Sykes 2003 {published data only}
    1. Sykes N, Thorns A. Sedative use in the last week of life and the implications for end‐of‐life decision making. Archives of Internal Medicine 2003;163:341‐4. - PubMed
Vitetta 2005 {published data only}
    1. Vitetta L, Kenner D, Sali A. Sedation and analgesia‐prescribing patterns in terminally ill patients at the end of life. American Journal of Hospice & Palliative Medicine 2005;22(6):465‐73. - PubMed

References to studies excluded from this review

Cameron 2004 {published data only}
    1. Cameron D, Bridge D, Blitz‐Lindeque J. Use of sedation to relieve refractory symptoms in dying patients. South African Medical Journal 2004;94(6):445‐9. - PubMed
Claessens 2012 {published data only}
    1. Claessens P, Menten J, Schotsmans P, Broeckaert B. Level of consciousness in dying patients. The role of palliative sedation: a longitudinal prospective study. American Journal of Hospice and Palliative Medicine 2012;29(3):195‐200. - PubMed
Cowan 2006 {published data only}
    1. Cowan JD, Clemens L, Palmer T. Palliative sedation in a southern Appalachian community. American Journal of Hospice and Palliative Medicine 2006;23(5):360‐8. - PubMed
Da Costa Miranda 2011 {published data only}
    1. Costa Miranda V, Souza Fede AB, Martins FD, Magalhaes NP, Lazzari Schaffhausser H, Riechelmann RP, et al. Doctor, how long?. European Journal of Cancer Care 2011;20:50‐5. - PubMed
Fainsinger 2000 {published data only}
    1. Fainsinger RL, Waller A, Bercovici M, Bengtson K, Landman W, Hosking M, et al. A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliative Medicine 2000;14:257‐65. - PubMed
Good 2005 {published data only}
    1. Good PD, Ravenscroft PJ, Cavenagh J. Effects of opioids and sedatives on survival in an Australian inpatient palliative care population. Internal Medicine Journal 2005;35(9):512‐7. - PubMed
Mercandante 2009 {published data only}
    1. Mercandante S, Intravaia G, Villari P, Ferrera P, Fabrizio D, Casuccio A. Controlled sedation for refractory symptoms in dying patients. Journal of Pain and Symptom Management 2009;37(5):771‐9. - PubMed
Morita 2005 {published data only}
    1. Morita T, Chinone Y, Ikenaga M, Miyoshi M, Nakaho T, Nishitateno K, et al. Efficacy and safety of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. Journal of Pain and Symptom Management 2005;30(4):320‐8. - PubMed
Porzio 2010 {published data only}
    1. Porzio G, Aielli F, Verna L, Micolucci G, Aloisi P, Ficorella C. Efficacy and safety of deep, continuous palliative sedation at home: a retrospective, single‐institution study. Supportive Care in Cancer 2010;18:77‐81. - PubMed
Rosengarten 2009 {published data only}
    1. Rosengarten OS, Lamed Y, Zisling T, Feigin A. Palliative sedation at home. Journal of Palliative Care 2009;25(1):5‐11. - PubMed
van Dooren 2009 {published data only}
    1. Dooren S, Veluw HTM, Zuylen L, Reitjens JAC, Passchier J, Rijt CCD. Exploration of concerns of relatives during continuous palliative sedation of their family members with cancer. Journal of Pain and Symptom Management 2009;38(3):452‐9. - PubMed

References to studies awaiting assessment

Castillo 2014 {published data only}
    1. Castillo MR, Garrido‐Bernet B, Benetez‐Rosario MA. Palliative sedation in a tertiary palliative care unit. Palliative Medicine. 2014; Vol. 28:665.
Lombana 2013 {published data only}
    1. Lombana M, Santacruz J, Pino L, Camacho M, Acevedo A, Buendia M, et al. Palliative sedation (PS) therapy, first experience of 4 years in a Colombian population. Supportive Care in Cancer. 2013; Vol. 21 Suppl 1:S108.
Ventafridda 1990 {published data only}
    1. Ventafridda V, Ripamonti C, deConno F, Tamburini M, Cassileth BR. Symptom prevalence and control during cancer patients last days of life. Journal of Palliative Care 1990;6:7‐11. - PubMed

Additional references

Billings 1996
    1. Billings JA, Block SD. Slow euthanasia. Journal of Palliative Care 1996;12:21‐30. - PubMed
De Graeff 2007
    1. Graeff A, Dean M. Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards. Journal of Palliative Medicine 2007;10(1):67‐85. - PubMed
Doyle 2008
    1. Doyle D, Woodruff R. The IAHCP Manual of Palliative Care. 2nd Edition. International Association for Hospice and Palliative Care Press, 2008.
Hickman 2001
    1. Hickman SE, Tilde VP, Tolle SW. Family reports of dying patients' distress: the adaptation of a research tool to assess global symptom distress in the last week of life. Journal of Pain and Symptom Management 2001;22(1):565‐74. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hirst 2009
    1. Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD003346] - DOI - PubMed
Jackson 2004a
    1. Jackson KC, Lipman AG. Drug therapy for delirium in terminally ill adult patients. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD004770] - DOI - PubMed
Jackson 2004b
    1. Jackson KC, Lipman AG. Drug therapy for anxiety in adult palliative care patients. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD004596] - DOI - PubMed
Jennings 2001
    1. Jennings AL, Davies AN, Higgins JPT, Anzures‐Cabrera J, Broadley KE. Opioids for the palliation of breathlessness in advanced disease and terminal illness. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD002066.pub2] - DOI - PMC - PubMed
Lynn 1997
    1. Lynn J, Teno JM, Phillips RS, Wu AW, Desbiens N, Harrold J, et al. Perceptions by family members of the dying experience of older and seriously ill patients. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Annals of Internal Medicine 1997;126(2):97‐106. - PubMed
Maltoni 2012a
    1. Maltoni M, Scarpi E, Rosati Ma, Derni S, Fabbri L, Martini F, et al. Palliative sedation in end‐of‐life care and survival: a systematic review. Journal of Clinical Oncology 2012;30(12):1378‐83. - PubMed
McWilliams 2010
    1. McWilliams K, Keeley PW, Waterhouse ET. Propofol for terminal sedation in palliative care: a systematic review. Journal of Palliative Medicine 2010;13(1):73‐6. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre; The Cochrane Collaboration. Review Manager. Version 5.3. Copenhagen: The Nordic Cochrane Centre; The Cochrane Collaboration, 2014.
Rietjens 2006
    1. Rietjens JA, Delden JJ, Heide A, Vrakking AM, Onwuteaka‐Philipsen BD, Maas PJ, et al. Terminal sedation and euthanasia: a comparison of clinical practices. Archives of Internal Medicine 2006;166:749‐53. - PubMed
Sterne 2014 [Computer program]
    1. Sterne JAC, Higgins JPT, Reeves BC on behalf of the development group for ACROBAT‐NRSI. A Cochrane Risk Of Bias Assessment Tool: for Non‐Randomized Studies of Interventions (ACROBAT‐NRSI). Version Version 1.0.0, 24 September 2014. The Cochrane Collaboration, Available from www.riskofbias.info (accessed 20 December 2014).
Wee 2008
    1. Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD005177.pub2] - DOI - PMC - PubMed

Publication types

Substances